Safer iPS cells

Until now, reprogramming fully differentiated cells into a pluripotent state has had a major drawback: the use of genome-integrating linkurl:retroviruses;http://www.the-scientist.com/blog/display/54750/ to do the job. But a new study published tomorrow in Science reports on the creation of reprogrammed cells without such integrating viruses. "The number one priority for labs working on iPS translation is to alleviate this problem of integration of viruses into the human genome," linkurl:Ali Bri

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
Until now, reprogramming fully differentiated cells into a pluripotent state has had a major drawback: the use of genome-integrating linkurl:retroviruses;http://www.the-scientist.com/blog/display/54750/ to do the job. But a new study published tomorrow in Science reports on the creation of reprogrammed cells without such integrating viruses. "The number one priority for labs working on iPS translation is to alleviate this problem of integration of viruses into the human genome," linkurl:Ali Brivanlou;http://www.rockefeller.edu/research/abstract.php?id=127 of Rockefeller University, who was not involved in the study, told The Scientist. "This paper addressed this issue head-on," he said, noting that the ability not to compromise the genome brings the technique "one important step closer to clinical applications." The researchers, led by linkurl:Konrad Hochedlinger,;http://www.hms.harvard.edu/dms/bbs/fac/Hochedlinger.html from Harvard Medical School, used adenoviruses to introduce the four reprogramming transcription factors (Oct4, Sox2, klf4, and c-Myc) into adult mouse somatic cells. Unlike retroviruses, used in the linkurl:first reprogramming studies;http://www.the-scientist.com/blog/display/53873/ and experiments until now, adenoviruses do not integrate into the mouse genome and do not cause tumor growth, which has been the major challenge of using induced pluripotent (iPS) cells for therapies. Instead, adenoviruses temporarily express high levels of the transcription factors, in most cases without integrating permanently into the genome. In early studies researchers did not know how long the transcription factors had to be induced in the somatic cell genome. They knew that using retroviruses would maintain the transcription factor expression indefinitely, giving them the best shot for reprogramming pluripotency. Eliminating retroviruses is a "safer way of producing iPS cells," Hochedlinger told The Scientist. The study is a benchmark, linkurl:Brock Reeve,;http://www.boston.com/news/globe/health_science/articles/2007/06/11/he_hopes_to_change_culture_of_institute/ executive director of the Harvard Stem Cell Institute told The Scientist, "but not a final one. It's not where the field is going to stop. People are going to continue to look at what chemical compounds can replace all viruses." The fact that the researchers replaced retroviruses with adenoviruses is an important step, added Brivanlou, but adenoviruses still can integrate into the genome, albeit rarely. In order for iPS cells to be at all clinically relevant "we need [a method] so to not at all worry about genetic compromise of the genome," he said. One thing the study did put to rest was a linkurl:suggestion made last month;http://www.ncbi.nlm.nih.gov/pubmed/18660799?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum that the site of viral integration on the genome might be more important than the transcription factors -- or cargo -- the virus was carrying. "It wasn't a clear prerequisite of the whole reprogramming process that introducing the four transcription factors alone was sufficient to reprogramming somatic cell into pluripotent state," Hochedlinger said. "Our data show that the four transcription factors are sufficient to produce iPS cells, and it's not necessary to use integrating viruses." The site of viral integration on the genome, on the other hand, does not seem to be important. Last month, linkurl:Douglas Melton's;http://www.hhmi.org/research/investigators/melton_bio.html group at Harvard used adenoviruses to linkurl:reprogram pancreatic cells;http://www.the-scientist.com/blog/display/54976/ into beta cells, using a different set of transcription factors -- turning one differentiated cell type into another differentiated cell type without going through a pluripotent stage. But the real advance, said Brivanlou, will be new reprogramming technologies that eliminate the need for viruses entirely.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Andrea Gawrylewski

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development